A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Aldeyra Therapeutics

Status and phase: Completed; Phase 2

Conditions: Conjunctivitis, Allergic

Treatments: Drug: ADX-102 Ophthalmic Drops (0.1%); Drug: Vehicle of ADX-102 Ophthalmic Drops; Drug: ADX-102 Ophthalmic Drops (0.5%)

Study type: Interventional

Funder types: Industry

Identifiers

NCT03012165

ADX-102-AC-004

Details and patient eligibility

About

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis.

Enrollment: 154 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• be at least 18 years of age of either gender and any race
• have a positive history of ocular allergies and a positive skin test reaction to a seasonal (grasses, ragweed, and/or trees) or perennial allergen (cat dander, dog dander, dust mites, cockroach) as confirmed by an allergic skin test within the past 24 months
• have a calculated visual acuity of 0.7 logMAR or better in each eye as measured using an ETDRS chart

Exclusion criteria

• have known contraindications or sensitivities to the use of the investigational product or any of its components
• have any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters (including but not limited to narrow angle glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis, pterygium or a diagnosis of dry eye)
• have had ocular surgical intervention within three (3) months prior to Visit 1 or during the study and/or a history of refractive surgery within the past six (6) months
• have a known history of retinal detachment, diabetic retinopathy, or active retinal disease
• have the presence of an active ocular infection (bacterial, viral or fungal) or positive history of an ocular herpetic infection at any visit
• be a female who is currently pregnant, planning a pregnancy, lactating, not using a medically acceptable form of birth control throughout the study duration and for 14 days prior to the installation of investigational product, or has a positive urine pregnancy test at Visit 1

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

154 participants in 3 patient groups, including a placebo group

ADX-102 Ophthalmic Drops (0.5%)

Experimental group

Description:

ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.

Treatment:

Drug: ADX-102 Ophthalmic Drops (0.5%)

ADX-102 Ophthalmic Drops (0.1%)

Experimental group

Description:

ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.

Treatment:

Drug: ADX-102 Ophthalmic Drops (0.1%)

Vehicle of ADX-102 Ophthalmic Drops

Placebo Comparator group

Description:

Vehicle of ADX-102 Ophthalmic Drops

Treatment:

Drug: Vehicle of ADX-102 Ophthalmic Drops